<DOC>
	<DOC>NCT01370707</DOC>
	<brief_summary>The aim of this study is to evaluate the efficacy and safety fo CJ-30001/CJ-30002.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects with Type 2 Diabetes Mellitus 20~69 years old BMI &lt; 30kg/m2 HbA1c between 7% and 11% receiving no oral antihyperglycemic agent for more than seven days for at least 8 weeks Willing to adhere to protocol requirements and sign a informed consent form Subjects with Type 1 Diabetes Mellitus FPG &gt; 270mg/dL Subjects having insulin treatment Subjects with acute or chornic metaboic acidosis Subjects with cardiovascular disease Subjects with chronic GI disease Subjects with a history of substance or alchol abuse within 1 year Subjects with a history of hypersensitivity to biguanide or aGI Subjects with hypopituitarism or hypocorticalism Subjects with cancer Subjects who take corticosteriods or plan to take corticosteroid AST and ALT &gt; 2.5 times the upper limit of normal Creatinine level &gt; 1.5mg/dL in male and 1.4mg/dL in female SBP &gt; 150mmHg or DBP &gt; 90mmHg Subjects who work the night shift Female subjects who are pregnant, breastfeeding or not using medically acceptable birth control Subjects who have participated in other study within 3 months Subjects judged to be unsuitable for this trial by investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>